Maravai LifeSciences Holdings, Inc.
MRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Maravai LifeSciences Holdings, Inc. focuses on Biotechnology services and products. Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North. With a market capitalization of $2.71B, it sits in mid-cap territory. It operates through two segments: TRILINK and CYGNUS.
Market Cap
$2.71B
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-72.72
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.10
ROE
-33.1%
ROA
-5.7%
Cash
$70.1M
Total Debt
$218.1M
Free CF
-$3.6M
52W Change
114.7%
Annual Financials
Cash vs Debt
Where MRVI stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, MRVI finished 29.07% above its 150-day moving average ($5.47) and 42.05% above its 200-day moving average ($4.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRVI overbought or oversold?
At the October 13, 2026 close, MRVI's RSI(14) was 44.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Maravai LifeSciences Holdings, Inc. carries $218.1M in total debt against $70.1M in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$3.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -33.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $883.0M (2022) to $185.7M (2025), a 79% decline worth watching.
MRVI's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MRVI.